Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2022-11-21 00:00:00 ET · period of report 2022-11-17 · accession 0000950170-22-025513 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-11-21 | 2022-11-17 | ACRV | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% | C - Cnv Deriv | — | +888.1K | 888.1K | New | — |
| D | 2022-11-21 | 2022-11-17 | ACRV | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% | C - Cnv Deriv | $0.00 | -2.19M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-17 | C | A | 888,130 | — | 888,130 | D | — | — | (F1) On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. |
| 2 | Derivative | Series B Preferred Stock | 2022-11-17 | C | D | 2,190,131 | $0.00 | 0 | D | — · — to — | 888,130 Common Stock | (F1) On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. |